HomeREGULATORY
REGULATORY

In Rare Moves, Parmodia and Istodax to Skip Price Listing for 2nd Time
(Nov.20.2017)

Kowa is taking a pass on the reimbursement listing of its hyperlipidemia hopeful Parmodia (pemafibrate) for the second consecutive time, as is Celgene for its lymphoma med Istodax (romidepsin), with the extremely rare moves signaling that drug makers’ price negotiations with regulators are getting tougher ...
(LOG IN FOR FULL STORY)